Beijing-based biotechnology platform Biocytogen has announced the completion of a 970 million yuan ($142 million) Series D+ round led by returning backer CMB International, a Hong Kong-based subsidiary of China Merchants Bank.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
